Kyverna Therapeutics Statistics

Total Valuation

KYTX has a market cap or net worth of $341.61 million. The enterprise value is $175.50 million.

Market Cap	341.61M
Enterprise Value	175.50M

Important Dates

The last earnings date was Wednesday, November 12, 2025, after market close.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	n/a

Share Statistics

KYTX has 43.80 million shares outstanding. The number of shares has increased by 56.07% in one year.

Current Share Class	43.80M
Shares Outstanding	43.80M
Shares Change (YoY)	+56.07%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	2.23%
Owned by Institutions (%)	26.15%
Float	19.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.25
P/TBV Ratio	2.25
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.16, with a Debt / Equity ratio of 0.03.

Current Ratio	5.16
Quick Ratio	5.05
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,383.14

Financial Efficiency

Return on equity (ROE) is -70.82% and return on invested capital (ROIC) is -45.75%.

Return on Equity (ROE)	-70.82%
Return on Assets (ROA)	-40.75%
Return on Invested Capital (ROIC)	-45.75%
Return on Capital Employed (ROCE)	-111.94%
Revenue Per Employee	n/a
Profits Per Employee	-$1.44M
Employee Count	112
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +57.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+57.58%
50-Day Moving Average	6.92
200-Day Moving Average	4.03
Relative Strength Index (RSI)	56.04
Average Volume (20 Days)	619,886

Short Selling Information

The latest short interest is 3.11 million, so 7.10% of the outstanding shares have been sold short.

Short Interest	3.11M
Short Previous Month	2.70M
Short % of Shares Out	7.10%
Short % of Float	15.58%
Short Ratio (days to cover)	4.28

Income Statement

Revenue	n/a
Gross Profit	-137.19M
Operating Income	-171.59M
Pretax Income	-160.99M
Net Income	-160.99M
EBITDA	-170.46M
EBIT	-171.59M
Earnings Per Share (EPS)	-$3.72

Full Income Statement

Balance Sheet

The company has $171.14 million in cash and $5.02 million in debt, giving a net cash position of $166.11 million or $3.79 per share.

Cash & Cash Equivalents	171.14M
Total Debt	5.02M
Net Cash	166.11M
Net Cash Per Share	$3.79
Equity (Book Value)	151.95M
Book Value Per Share	3.47
Working Capital	141.05M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$157.25 million and capital expenditures -$538,000, giving a free cash flow of -$157.78 million.

Operating Cash Flow	-157.25M
Capital Expenditures	-538,000
Free Cash Flow	-157.78M
FCF Per Share	-$3.60

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KYTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-56.07%
Shareholder Yield	-56.07%
Earnings Yield	-47.13%
FCF Yield	-46.19%

Analyst Forecast

The average price target for KYTX is $20.25, which is 159.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.25
Price Target Difference	159.62%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-12.68%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1